Genus non-exec bulks up stake
A round-up of the biggest director deals today so far.
Professor Barry Furr, a non-executive director at the animal breeding technology group Genus, has spent £30,000 more than doubling his stake in the animal breeding company, the firm confirmed today.
He bought 5,000 shares at 600p a time and now has 8,000.
Furr, a former chief scientist for the drug giant AstraZeneca, bought his initial stake of 3,000 shares at 680p a time in October.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Genus sells breeding technology products to livestock and farmers.
Top Director Buys
Value: £61,350
Value: £30,000
Value: £24,880
Value: £14,880
Top Director Sells
Value: £410,000
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Review: Eden Roc Cap Cana – fun, sun and golf in the Caribbean
Travel Eden Roc Cap Cana in the Dominican Republic offers everything from relaxing by the pool to a world-class golf course
-
Reeves delays cash ISA reform, but savers are not out of the woods yet
The chancellor has reportedly delayed plans to cut the cash ISA limit, which were set to be announced at Mansion House on 15 July, and will take more time to consult with the industry